Unlocking MASH Care: Exploring Cutting-Edge Pharmacological Advances and Lifestyle Strategies with Allysa Saggese, NP

As treatments for metabolic dysfunction-associated steatohepatitis (MASH) progress, doctors are excited yet mindful of the importance of lifestyle changes. With two FDA-approved therapies available, balancing medication and healthy habits is vital.

At the 2025 Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) conference, nurse practitioner Allysa Saggese from Weill Cornell shared insights on discussing liver health with patients. She emphasized the importance of lifestyle modifications alongside medications like resmetirom and semaglutide in managing MASH.

Saggese described the current state of MASH management as exciting. “It’s crucial to stay informed about these new options,” she noted. Clinicians must be prepared for patient inquiries, knowing which treatment may be best suited for them.

Resmetirom, approved in March 2024, is the first FDA-approved drug for treating noncirrhotic MASH, meant to be used with diet and exercise. Semaglutide followed in August 2025, providing another option for treatment. “What’s great about semaglutide is its benefits extend beyond liver health. It helps with blood sugar control, weight loss, and even cardiovascular conditions,” Saggese explained. This multi-faceted approach offers clinicians more tools to support their patients.

Having two medication options opens new avenues for discussions. Saggese believes this variety will encourage deeper conversations about MASH treatment that simply weren’t possible before.

Despite the excitement surrounding new drugs, Saggese strongly advocates for lifestyle modifications, including diet and physical activity. “It’s essential to integrate care from different specialists,” she said. A team approach can significantly enhance treatment outcomes.

In recent surveys, around 60% of healthcare professionals expressed a desire for more patient education on MASH. Educating patients can empower them to make informed decisions about their health.

In summary, MASH management is evolving with new treatments, but the foundation remains in healthy lifestyle choices and collaborative care. Maintaining a balanced approach will be key to helping patients achieve the best outcomes.

For more on recent advancements, check out the following sources:

Source link

medicine,medical,news,drugs,treatments,fda,health,healthcare,science,research,pipeline,pharmaceuticals,clinicians,insight,interviews,doctors,providers,allergy,pulmonology,dermatology,ophthalmology,cardiology,endocrinology,diabetes,psychiatry,internal medicine,primary care,rheumatology,gastroenterology,hematology,rare disease,infectious disease

Post Views: 31